MTAP Target Evaluation Report: Biology, Validation, Competition, IP, and R&D Strategy
MTAP Target Evaluation Report: Biology, Validation, Competition, IP, and R&D Strategy was generated using PatSnap Life Sciences MCP Servers. Target & Disease MCP contributed the biology and disease context, while Clinical Trials MCP contributed validation evidence and clinical competition signals.
Why this report exists: it shows how AI agents can use PatSnap MCP data to produce target evaluation workflows covering biology, validation, competition, IP, and R&D recommendation. Explore PatSnap Life Sciences MCP Servers for AI agents.
Executive Summary
This MTAP Target Evaluation Report is generated from PatSnap MCP data. MTAP is best evaluated as a biomarker and synthetic-lethality context rather than a conventional drug target: direct MTAP-mapped drug counts are low, but Clinical Trials MCP found 46 MTAP-deletion trial records and PRMT5-related result records that make the MTAP-loss opportunity clinically important.
Target
MTAP
UniProt Q13126
Drug Count
8
4 development-stage assets directly mapped to MTAP
Trials
46
MTAP-title clinical trials retrieved by Clinical Trials MCP
Results
14
Clinical Trials MCP result records
Target Attractiveness Snapshot
Biology
Target & Disease MCP describes MTAP as methylthioadenosine phosphorylase, catalyzing MTA cleavage to adenine and 5-methylthioribose-1-phosphate in the methionine salvage pathway.
Disease Context
The oncology value comes from MTAP deletion creating a metabolic state that can sensitize tumors to PRMT5-pathway or related synthetic-lethality strategies.
Strategy
Use MTAP as a patient-selection and indication-definition asset, especially for PRMT5/MTA-cooperative programs in NSCLC, mesothelioma, and other solid tumors.
Overall Target Evaluation Score: 72/100
- Biology: Metabolic biology is clear but MTAP is usually a biomarker context.
- Clinical validation: Clinical Trials MCP found 46 MTAP-title trials; direct MTAP target trial mapping was sparse.
- Competition: Competition is growing through PRMT5 and MTAP-deletion programs.
- White space: White space exists in diagnostics, combinations, and tumor-type prioritization.
Biology and Disease Rationale
MTAP catalyzes phosphorolytic cleavage of S-methyl-5-thioadenosine and supports methionine salvage after MTA generation from S-adenosylmethionine. Loss of MTAP can alter MTA metabolism and create exploitable dependencies in adjacent pathways, especially PRMT5 biology.
Clinical Trials MCP direct target search returned no MTAP-targeted solid-tumor trials, but title-based retrieval found 46 MTAP-deletion trial records. Examples include HSK41959 in MTAP advanced solid tumors, GTA182 plus volmetinib in MTAP homozygous-deleted NSCLC, BMS-986504 in MTAP-deficient mesothelioma, and BMS-986504 plus pemetrexed in MTAP-deleted metastatic solid tumors.
Explore PatSnap Life Sciences MCP Servers for AI agents
Validation and Clinical Competition
| Biomarker trial volume | A title search for MTAP returned 46 clinical trial records, showing that MTAP deletion is already operationalized in trial design. |
| NSCLC precision strategy | GTA182 plus volmetinib is recruiting in locally advanced or metastatic NSCLC with MTAP homozygous deletion. |
| Mesothelioma expansion | SELECTmeso tests BMS-986504 in MTAP-deficient relapsed mesothelioma. |
| Direct-target caveat | Direct MTAP target mapping returned zero solid-tumor trials, supporting the interpretation of MTAP as a biomarker context rather than a classical target. |
IP and Competitive Strategy
MTAP IP should focus on diagnostic assays, homozygous-deletion definitions, patient-selection claims, PRMT5/MTA-cooperative combinations, tumor-type expansion, and methods of treating MTAP-deleted cancers rather than MTAP inhibition itself.
Recommendation
MTAP should be handled as a biomarker-led target-evaluation page. The commercial opportunity is real, but the asset strategy belongs to synthetic-lethality programs and companion diagnostics more than direct MTAP pharmacology.
Bottom line: This MTAP Target Evaluation Report is generated from PatSnap MCP data. MTAP is best evaluated as a biomarker and synthetic-lethality context rather than a conventional drug target: direct MTAP-mapped drug counts are low, but Clinical Trials MCP found 46 MTAP-deletion trial records and PRMT5-related result records that make the MTAP-loss opportunity clinically important.
Start building target evaluation agents with PatSnap Life Sciences MCP Servers
